Christobel Selecky - 16 Jan 2026 Form 4 Insider Report for ImmunityBio, Inc. (IBRX)

Role
Director
Signature
/s/ Philip LoScalzo, as Attorney-in-Fact
Issuer symbol
IBRX
Transactions as of
16 Jan 2026
Net transactions value
-$214,150
Form type
4
Filing time
21 Jan 2026, 20:33:48 UTC
Previous filing
20 Jun 2025
Next filing
24 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Selecky Christobel Director C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO /s/ Philip LoScalzo, as Attorney-in-Fact 21 Jan 2026 0001849739

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IBRX Common Stock Options Exercise $149,000 +50,000 $2.98 50,000 16 Jan 2026 Direct
transaction IBRX Common Stock Sale $250,000 -50,000 -100% $5.00 0 16 Jan 2026 Direct F1
transaction IBRX Common Stock Options Exercise $74,500 +25,000 $2.98 25,000 20 Jan 2026 Direct
transaction IBRX Common Stock Sale $187,650 -25,000 -100% $7.51* 0 20 Jan 2026 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IBRX Stock Option (right to buy) Options Exercise $0 -50,000 -30% $0.000000 117,937 16 Jan 2026 Common Stock 50,000 $2.98 Direct F3
transaction IBRX Stock Option (right to buy) Options Exercise $0 -25,000 -21% $0.000000 92,937 20 Jan 2026 Common Stock 25,000 $2.98 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2025.
F2 Represents the weighted average share price of an aggregate total of 25,000 shares sold in the price range of $7.50 to $7.52 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 One hundred percent (100%) of the shares subject to the award vested on June 12, 2023, the date immediately preceding the 2023 annual meeting of stockholders.

Remarks:

Exhibit 24 - Power of Attorney